Aetion and Cegedim Health Data announce new partnership to power real-world evidence research in Europe
July 08 2020 - 11:00AM
Aetion and Cegedim Health Data announce new partnership to power
real-world evidence research in Europe
Aetion and Cegedim Health Data announce
new partnership to power real-world evidence research in
Europe
Collaboration enables use of clinical data to
address critical treatment questions as biopharma and regulators
respond and adapt to COVID-19
July 8th, 2020
- Today Aetion and
Cegedim Health Data announced a new
partnership to integrate Cegedim’s
THIN® European real world
data (RWD) into Aetion Evidence Platform® (AEP). AEP analyses data
from the real world, including claims, electronic health records,
registries, and clinical trial data to produce transparent, rapid,
and scientifically-validated real world evidence (RWE) on the
safety, effectiveness, and value of medical
interventions.
This new collaboration with Cegedim Health Data
will enable Aetion’s clients, including top biopharma companies,
leading payers, and regulatory agencies to employ leading
trans-Atlantic RWD to unlock essential insights about treatments.
Cegedim’s THIN database — which stands for The Health Improvement
Network — includes fully anonymized electronic health records from
France, UK, Spain, Belgium and Romania, and provides detail on
diagnoses, treatments, clinical outcomes and interventions. The
data provides a robust view of treatment use and outcomes — making
it a particularly valuable data source for answering COVID-19
treatment questions. When analyzed in Aetion’s platform, THIN data
can be transformed into evidence to inform clinical trial planning,
regulatory submissions, and value assessment decisions.
Carolyn Magill, CEO,
Aetion, comments: “Over the last few months, COVID-19 has changed
the drug development landscape, as leading biopharma companies,
regulators, and health technology assessment bodies (HTAs) alike
look to real world data to urgently answer questions on treatment
utilization, safety, and effectiveness. Through this partnership
with Cegedim, our aim is to help global biopharma companies quickly
generate decision-grade real-world evidence by expanding our data
sources and capabilities in the EU.”
Gilles Paubert, Global
Head, Cegedim Health Data, adds: “Cegedim is committed to enabling
advancements in patient outcomes and expanding its involvement in
partnerships to ensure that longitudinal and representative RWD is
accessible to all those who require it. The clinically rich data
that we capture through THIN, which has a history dating back to
1994, will help clients using Aetion’s platform explore the nuance
of each particular dataset, be it therapeutic area-specific or
region-specific, to reveal critical insights needed to bring a new
drug to market and deliver efficacious treatments to patients
faster.”
Aetion partners with the world's leading
real-world data providers to enable streamlined access to data for
analysis in its platform. This partnership helps it expand its
global footprint and serve clients conducting EU-focused
research.
Global regulatory agencies and HTAs are
increasingly adopting RWE, especially as these groups work to
respond to the COVID-19 pandemic. The European Medicines Agency
(EMA) plans to incorporate real world data to complement evidence
from clinical trials and to help streamline regulatory and
decision-making processes for COVID-19 vaccine development and
authorisation. Many European HTAs already use RWE for value
assessments, and a number of others, including UK’s NICE, Germany's
IQWiG, Belgium’s INAMI/RIZIV have committed to expanding its use in
their assessments this year.
About Aetion: Aetion is a health care technology
company that delivers real-world evidence for life sciences
companies, payers, and regulatory agencies. The Aetion Evidence
Platform® analyzes data from the real world to produce transparent,
rapid, and scientifically validated answers on costs and outcomes.
Founded by Harvard Medical School faculty with decades of
experience in epidemiology and health outcomes research, Aetion
informs health care's most critical decisions — what works best,
for whom, and when — to guide product development,
commercialization, and payment innovation into health care’s modern
era.
Aetion is based in New York City, and
backed by investors including New Enterprise Associates (NEA),
Flare Capital Partners, Lakestar, Town Hall Ventures, McKesson
Ventures, Sanofi Ventures, Amgen Ventures, UCB, and Horizon Health
Services, Inc. Learn more at aetion.com and follow us at
@aetioninc.
About Cegedim Health
Data: Cegedim Health Data is part of the Cegedim Group, an
innovative Technology, Services and Real World Data Company that
has specialised in the healthcare field for more than 50 years.
Cegedim Health Data provides Real World Data and Evidence (RWD-E)
to drive cutting edge improvements in patient outcomes. With a data
history of over 24 years and millions of anonymised patient records
immediately accessible from our THIN® (The Health Improvement
Network) European database.
To learn more,
visit www.cegedim-health-data.com
About Cegedim: Founded in 1969, Cegedim is an
innovative technology and services company in the field of digital
data flow management for healthcare ecosystems and B2B, and a
business software publisher for healthcare and insurance
professionals. Cegedim employs almost 5,000 people in more than 10
countries and generated revenue in excess of €500 million in 2019.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.comAnd
follow Cegedim on Twitter: @CegedimGroup, LinkedIn and
Facebook.
Aude
BalleydierCegedimMedia Relations and
Communications ManagerTel.: +33 (0)1 49 09 68
81aude.balleydier@cegedim.com |
Gilles PaubertCegedim Health Data
Global Head of Health DataTel : +33 (0)1 49 09 67 07
gilles.paubert@cegedim.fr |
Josephine TimminsNeo PR, on behalf of
Cegedim UK Account Director Tel : +44 (0) 1296
733867 cegedim@neopr.co.uk |
|
- CegedimHealthData_Aetion_08072020_eng APPROVED
Cegedim (EU:CGM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cegedim (EU:CGM)
Historical Stock Chart
From Oct 2023 to Oct 2024